Bavarian Nordic vaccine shows promising results in HIV infected patients  

MVA-BN nef has shown promise in a clinical study in HIV infected patients on antiretroviral therapy

Bavarian Nordic’s pilot HIV vaccine candidate, MVA-BN nef encoding the Nef protein of HIV, has shown promise in a clinical phase I/II study in 14 HIV infected patients on antiretroviral therapy. In a press release on the company's website Bavarian Nordic's CEO comments, “This is a major milestone for our lead platform technology. Up to 11 months after stopping antiretroviral therapy the levels of HIV in 7 patients remained below their pre-therapy level. The MVA-BN vector... has now been shown also to be safe and very immunogenic in immune compromised individuals.”


Bavarian Nordic is a world leader in the research, development and manufacturing of vaccines and immunotherapy against infectious diseases. The company has ongoing clinical programs in HIV and smallpox, as well as pre-clinical and research programmes within a number of infectious diseases. Two weeks ago the company gained a massive order to deliver a potential 30 million doses of smallpox vaccine to the US Department of Health and Human Services.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×